Acceleron Pharma, Inc. (XLRN)

Oncology Corporate Profile

Stock Performance

30.7000
-0.3300

HQ Location

128 Sidney Street
Cambridge, MA 2139

Company Description

Acceleron's goal is to develop innovative therapies. Acceleron has built in-house drug development capabilities, allowing them to focus their creativity and innovation on the biology of the Growth and Differentiation Factor (GDF) protein family, while streamlining the development of novel therapies.

Website: http://www.acceleronpharma.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ACE-536type II activin receptorAnemia in Myelodysplastic Syndrome (MDS)IIICelgene
sotatercept / ACE-011activin inhibitorAnemia in Myelodysplastic Syndrome (MDS)IICelgene
dalantercept / ACE-041ALK inhibitorHepatocellular carcinoma (HCC)II
luspaterceptactivin receptor type IIB fusion proteinMyelodysplastic Syndrome (MDS)II
dalantercept / ACE-041ALK1 inhibitorRenal cell carcinoma (RCC)II
ACE-031ActRIIB inhibitorCancer related bone lossI
dalantercept / ACE-041ALK1 inhibitorOvarian cancerI

View additional information on product candidates here »

Pipeline image

Source


http://www.acceleronpharma.com

Recent News Headlines

Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association

6/10/2016 10:54 am

(NASDAQ) June 10, 2016 - Longer term data with investigational drug luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden, and improved patient reported quality of life measures in patients with beta-thalassemia.

Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association

6/10/2016 10:53 am

(NASDAQ) June 10, 2016 - Preliminary results show that treatment with investigational drug luspatercept results in clinically meaningful increases in hemoglobin and durable transfusion independence in patients with lower risk myelodysplastic syndromes.

Tiny Cameras to See in the Intestines

3/1/2016 11:04 am

(Wall Street Journal) Feb 29, 2016 - Many of the products are still in development, and none has replaced widely used scope procedures such as the colonoscopy, which doctors still consider the best screening method for colorectal cancer.

Old Red Dye Shows Promise as New Cancer Foe

2/26/2016 11:04 am

(Reuters) Feb 26, 2016 - Modern cancer drugs supercharge immune systems, target specific gene mutations and pack modified viruses into vaccines. Amid the increasing sophistication, one investigational treatment stands out for its simplicity.

Chemo Better Option Following Pancreatic Cancer Surgery: Study

2/26/2016 11:04 am

(VUMC/news@Vanderbilt) Feb 25, 2016 - A multicenter study led by Vanderbilt University Medical Center (VUMC) investigators found that pancreatic cancer patients who underwent surgery and received chemotherapy lived longer and had fewer cancer recurrences in other parts of the body than patients who also received chemoradiation therapy.

Most Recurrences of HPV-Positive Oropharyngeal Cancer Can Be Found Through Imaging and Physical Exams within Six Months after Treatment

2/19/2016 10:05 am

(ASTRO) Feb 18, 2016 - For patients treated with definitive radiation therapy (RT) for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at three months and physical exams during the six months following treatment, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

OXiGENE Receives European Orphan Drug Designation for OXi4503 to Treat Acute Myeloid Leukemia

12/18/2015 11:05 am

(Oxigene) Dec 17, 2015 - OXiGENE, Inc., a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the European Commission has granted orphan drug designation to OXi4503 for the treatment of acute myeloid leukemia (AML).

F.D.A. Proposes Ban on Indoor Tanning for Minors to Fight Skin Cancer

12/18/2015 11:05 am

(New York Times) Dec 18, 2015 - The Food and Drug Administration has proposed banning people under 18 from using tanning beds, in what medical experts say is a major step toward reducing the risk of skin cancer in the United States.

Galena Biopharma To Sell Zuplenz® (ondansetron) Oral Soluble Film, Completing Divestiture Of Commercial Operations

12/18/2015 11:05 am

(TheStreet) Dec 18, 2015 - Galena Biopharma, Inc., a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced it has entered into an agreement for the sale of its Zuplenz® (ondansetron) Oral Soluble Film product to Midatech Pharma Plc in a deal valued at up to $29.75 million, with $3.75 million cash upfront and up to $26 million in additional cash upon the achievement of certain sales milestones.

Karmanos Cancer Institute Announces New Leadership Roles for Elisabeth Heath, M.D., FACP, and Ulka Vaishampayan, M.D.

12/18/2015 11:05 am

(Karmanos Cancer Institute) Dec 17, 2015 - Gerold Bepler, M.D., Ph.D., president and CEO of the Barbara Ann Karmanos Cancer Institute recently announced the promotion of two physician scientists: Elisabeth Health, M.D., FACP; and Ulka Vaishampayan, M.D. Each will take on their new leadership roles effective immediately.

'Three Tyrannies' Threaten Primacy of Science in Oncology

12/18/2015 11:04 am

(MedPage Today) Dec 17, 2015 - Although most oncologists would probably say that clinical trials should be the gold standard for determining the standard of care, the world of clinical medicine still doesn't always work that way.

Prostate Cancer Discovery May Make It Easier to Kill Cancer Cells

12/18/2015 11:04 am

(University of Virginia) Dec 17, 2015 - A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy.

BMS and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program

12/18/2015 11:04 am

(Bristol-Myers) Dec 17, 2015 - Bristol-Myers Squibb Company and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) today announced that they have entered into a collaborative agreement as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.

Adaptimmune Announces Initiation of Study to Evaluate its New Affinity Enhanced T-Cell Therapy Targeting MAGE-A10 in Patients with NSCLC, the Most Common Form of Lung Cancer

12/18/2015 11:03 am

(Adaptimmune) Dec 17, 2015 - Adaptimmune Therapeutics plc, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 percent of lung cancers.

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

12/18/2015 11:03 am

(Yahoo! Finance) Dec 18, 2015 - Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1b, multicenter, international, open-label study of AG-221 or AG-120 in combination with induction and consolidation therapy in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are eligible for intensive chemotherapy.

Uncovering Potentially 'Concerning' Variation in Cancer Screening Follow-ups

12/18/2015 11:03 am

(Dartmouth) Dec 18, 2015 - Follow-up times of abnormal screening exams were shorter for breast cancer than they were for colorectal and cervical cancers, according to a recent study involving more than one million individuals who underwent these screenings.

Scientists Discover How Tumours Hijack Body's Wound Healing Process

12/18/2015 11:03 am

(ICR [UK]) Dec 17, 2015 - SCIENTISTS have discovered how cells that usually help repair wounds can switch from friend to foe – and instead escalate tumour growth and cancer spread according to research published today in Cell Reports.

Pancreas Cancer Liquid Biopsy Flows From Blood-Borne Packets of Tumor Genes

12/18/2015 11:03 am

(MD Anderson) Dec 17, 2015 - Pancreatic cancer tumors spill their molecular secrets into the blood stream, shedding their complete DNA and RNA wrapped inside protective lipid particles that make them ripe for analysis with a liquid biopsy, researchers at The University of Texas MD Anderson Cancer Center report online at the Annals of Oncology.

'Smart Fat Cells' Cross Blood-Brain Barrier to Catch Early Brain Tumors

12/18/2015 11:03 am

(Penn Medicine) Dec 17, 2015 - An MRI contrast agent that can pass through the blood-brain barrier will allow doctors to detect deadly brain tumors called gliomas earlier, say Penn State College of Medicine researchers.

Cancer-Fighting Tea Set for Clinical Trials in Ontario

12/18/2015 11:03 am

(CBC) Dec 18, 2015 - A Calgary company is involved in a clinical trial attempting to harness the potential cancer-fighting properties of a common weed.

The Science -- Or Lack Of It -- Behind Genetic Tests Offered In The Workplace

12/18/2015 11:03 am

(Forbes) Dec 18, 2015 - All genetic tests are not created equal. That's the key point missing from a high-profile article in Wednesday's Wall Street Journal examining companies that offer genetic tests to employees – not as a tool for managers, but rather as a high-end wellness benefit, like subsidized gym membership.

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

12/6/2015 02:34 pm

(TheStreet) Dec 5, 2015 - Luspatercept increased hemoglobin levels and generated transfusion independence in patients with lower risk myelodysplastic syndromes.

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

6/12/2015 11:12 am

(Morningstar) June 12, 2015 - Acceleron Pharma Inc. today announced that new preliminary results from the ongoing phase 2 clinical trials of luspatercept in patients with lower risk myelodysplastic syndromes (MDS) and in patients with beta-thalassemia were highlighted in oral presentations at the 20th Congress of the European Hematology Association in Vienna, Austria.

Celgene and Acceleron Select Luspatercept to Advance to Phase 3 in Myelodysplastic Syndromes

4/30/2015 12:11 pm

(Yahoo! Finance) Apr 30, 2015 - Acceleron Pharma Inc. today announced that Acceleron and its collaboration partner, Celgene Corporation, plan to initiate a Phase 3 program with luspatercept in myelodysplastic syndromes and beta-thalassemia by year-end 2015.

In Big Shift, FDA Plans to Let 23andMe Market Genetic Tests to Consumers

2/20/2015 11:01 am

(Forbes) Feb 19, 2015 - More than a year after the Food and Drug Administration barred 23andMe from marketing a broad-based genetic testing service, it looks like the FDA plans to shift gears and allow such tests to be sold directly to consumers.

Acceleron/Celgene Two-Pronged Attack on Rare Blood Disorders

12/9/2014 04:06 pm

(PharmaTimes [UK]) Dec 8, 2014 - Acceleron Pharma and Celgene Corp have unveiled positive mid-stage data at the American Society of Hematology meeting in San Francisco on two compounds - luspatercept and sotatercept - which are being developed to target rare blood disorders.

Acceleron Drugs Reduce Anemia Caused by Rare Blood Disorders

12/7/2014 06:24 pm

(TheStreet) Dec 7, 2014 - Celgene has worldwide clinical development and marketing rights to the two Acceleron drugs, known as luspatercept and sotatercept.

Alchemia Updates Timeline for Completion of Pivotal Phase III Trial of HA-Irinotecan in Metastatic Colorectal Cancer

6/6/2014 06:05 am

(MarketWatch) June 5, 2014 - Alchemia Limited announced today that they expect to report the top-line results from the pivotal Phase III trial of HA-Irinotecan in metastatic colorectal cancer (mCRC) before the end of 3Q CY 2014.

Acceleron to Report New Encouraging Interim Clinical Data from Phase 2 Trial of Dalantercept in Renal Cell Carcinoma at the 50th Annual Meeting of the American Society of Clinical Oncology

5/15/2014 02:08 pm

(Yahoo! Finance) May 14, 2014 - Acceleron Pharma Inc today reported new interim data from the ongoing phase 2 clinical trial of dalantercept, an activin receptor-like kinase 1 (ALK1) inhibitor, in combination with Inlyta (axitinib) in patients with advanced renal cell carcinoma (RCC).

Acceleron to Report New Encouraging Interim Clinical Data from Phase 2 Trial of Dalantercept in Renal Cell Carcinoma at the 50th Annual Meeting of the American Society of Clinical Oncology

5/15/2014 09:00 am

(Yahoo! Finance) May 14, 2014 - Acceleron Pharma Inc today reported new interim data from the ongoing phase 2 clinical trial of dalantercept, an activin receptor-like kinase 1 (ALK1) inhibitor, in combination with Inlyta (axitinib) in patients with advanced renal cell carcinoma (RCC).

Overexpressed Protein the Culprit in Certain Thyroid Cancers

10/15/2013 11:05 am

(UT Southwestern) Oct 14, 2013 - A specific protein once thought to exist only in the brain may play a crucial role in a deadly form of thyroid cancer, as well as other cancers, and provide a fresh target for researchers seeking ways to stop its progression.

PQRS REMINDERS: To Avoid Medicare Payment Cuts, Group Practices Must Register for PQRS by October 15 and Eligible Professionals Must Begin Reporting

10/10/2013 11:05 am

(ASCO) Oct 9, 2013 - Group Practices that do not register to report through PQRS by October 15, 2013, can expect a 1.5 percent Medicare payment reduction on Part B physician fee schedule (PFS) services in 2015, but practices that do report can expect a 0.5 percent PFS payment increase in 2014 and have their participation noted on CMS Physician Compare Site.

New Discoveries for Cancer Risk: Researchers Worldwide Take Part in One of History's Largest Scientific Consortium

10/9/2013 11:05 am

(Boerse-Go.de) Oct 9, 2013 - Hundreds of researchers from North America, Europe, Australia and Asia have joined together in a consortium to identify the genetic basis of the five most common forms of cancer - breast, prostate, lung, ovarian and colorectal.